KPTI insider trading — Karyopharm Therapeutics Inc.
Over the last 90 days, insiders at Karyopharm Therapeutics Inc. (KPTI) made 0 open-market purchases worth $0 and 3 open-market sales worth $2K, making them net sellers by $2K. The largest sale was by Poulton Stuart (EVP, Chief Development Officer), who sold 189 shares for $1K on Jul 28, 2026.
Updated Oct 16, 2026.
Recent KPTI insider transactions
Every Form 4 filed by Karyopharm Therapeutics Inc. officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Abate Kristin | Chief Accounting Officer | S · Sale | Direct | 378 | $1.19 | $450 | Form 4 |
| Sep 1, 2026 | Abate Kristin | Chief Accounting Officer | S · Sale | Direct | 19 | $2.02 | $38 | Form 4 |
| Jul 28, 2026 | Poulton Stuart | EVP, Chief Development Officer | S · Sale | Direct | 189 | $7.10 | $1K | Form 4 |
KPTI insider trading FAQ
Are insiders buying KPTI stock?
Not on the open market. In the last 90 days, Karyopharm Therapeutics Inc. insiders made no open-market purchases, and 3 open-market sales totaling $2K. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading KPTI?
Recent sellers: Abate Kristin, Poulton Stuart.
Where does KPTI insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.